Mesoblast Eyes Japan Conditional Approval After New RA Cell Therapy Data
Executive Summary
Mesoblast is looking at a possible conditional approval pathway in Japan for its cell therapy for rheumatoid arthritis, based on promising new results from a Phase II study that showed a durable response for at least nine months from a single “dose”.